William B. Mattes
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Senior Scientific Advisor
Also affiliated: GenVec (2006); Novartis (Switzerland) (1990); Center for Food Safety and Applied Nutrition (2023–2024); Centre National de la Recherche Scientifique (1996); National Institutes of Health (1985–1986); United States Food and Drug Administration (2015–2025); Canon (Japan) (2010); Johns Hopkins University (1982–1983); University of Kansas (2005); Schlumberger (British Virgin Islands) (2012); University of Alberta (1988); Eli Lilly (United States) (2008); Pfizer (United States) (2004); Mario Negri Institute for Pharmacological Research (1990); Critical Path Institute (2007–2010); Institut Gustave Roussy (1996); Ludwig Boltzmann Institut für Epilepsie und Neuromuskuläre Erkrankungen (2008); Summit University (1997); National Cancer Institute (1985–1988); Food and Drug Administration (2025); Connecticut Center for Primary Care (1993); Kalamazoo College (2004); UConn Health (1988–1993); W.E. Upjohn Institute for Employment Research (1997)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
William B. Mattes, Senior Scientific Advisor at the National Center for Toxicological Research, focuses his research on understanding the toxicological effects of various compounds and developing predictive models for drug safety. His work investigates mechanisms of toxicity, particularly in relation to cellular functions and potential impacts on human health. Mattes has published research on metabolomics as a translational tool for precision medicine and on the identification of concepts and terminology for multicomponent biomarkers.
His recent publications explore drug-induced cardiotoxicity using induced pluripotent stem cell-derived cardiomyocytes and the effects of specific compounds, such as pexidartinib, on liver mitochondrial function in primary human hepatocytes. Mattes also works on validating new approach methodologies (NAMs) for toxicity screening and drug development, including the use of human-based multiple organ microphysiological systems (MPS) to generate kinetic and organ toxicity data. His research network includes collaborators from the National Center for Toxicological Research, such as Li Pang, Laura K. Schnackenberg, Katy S Papineau, and Lijun Ren.
Mattes' scholarship is characterized by a significant body of work, with 99 total publications and 3,869 citations, contributing to his h-index of 33. He is recognized as a highly cited researcher, indicating a substantial impact in his field. His active lab website suggests ongoing research and engagement within the scientific community.
Metrics
- h-index: 33
- Publications: 99
- Citations: 3,876
Selected Publications
-
Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development (2025)
-
Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations (2025)
-
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024)
-
Metabolomics as a Truly Translational Tool for Precision Medicine (2021)
-
Qualification of Safety Biomarkers for Application to Early Drug Development (2020)
-
Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice (2020)
-
Determination of structural factors affecting binding to mu, kappa and delta opioid receptors (2020)
-
Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors (2020)
-
Comprehensive Identification and Characterization of Human Secretome Based on Integrative Proteomic and Transcriptomic Data (2019)
-
Abstract 17363: Inter-Individual Heterogeneity Among Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Response to Kinase Inhibitors (2018)
-
Computational identification of structural factors affecting the mutagenic potential of aromatic amines: study design and experimental validation (2018)
-
Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes (2018)
-
Induced Pluripotent Stem Cell-Derived Cardiomyocytes: An In Vitro Model to Predict Tyrosine Kinase Inhibitor (TKI)-Induced Structural Cardiotoxicity (2017)
-
Regulatory landscapes for biomarkers and diagnostic tests: Qualification, approval, and role in clinical practice (2017)
-
Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans (2017)
Collaboration Network
Top Collaborators
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Metabolomics as a Truly Translational Tool for Precision Medicine
- Metabolomics as a Truly Translational Tool for Precision Medicine
- Metabolomics as a Truly Translational Tool for Precision Medicine
- Metabolomics as a Truly Translational Tool for Precision Medicine
- Metabolomics as a Truly Translational Tool for Precision Medicine
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
Similar Researchers
Based on overlapping research topics